Description
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma
Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control
: Human wild-type HCT116 cell line (ab288559). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-DPP4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Dipeptidyl peptidase 4 also known as DPP4 or CD26 functions as a serine exopeptidase. This enzyme is involved in cleaving dipeptides from the N-terminus of polypeptides. DPP4 with a mass of approximately 110 kDa is expressed in various tissues such as the liver intestines kidney and lymphocytes. It exists in both a membrane-bound form and a soluble form in blood plasma.
Biological function summary
DPP4 plays a significant role in glucose metabolism and immune function. The enzyme interacts with members of the immune system and regulates proteins such as chemokines growth factors and neuropeptides. DPP4 acts independently and is not known to be part of a larger complex. It modulates biological processes by inactivating peptide hormones and signaling molecules which impacts glucose homeostasis and immune responses.
Pathways
DPP4 impacts the incretin signaling pathway and the immune response pathway. Incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are substrates of DPP4 and play important roles in glucose metabolism. DPP4 also interacts with proteins such as adenosine deaminase (ADA) which impacts T-cell function and immune regulation. The regulation of these pathways by DPP4 influences metabolic and immune health.
DPP4 involvement is relevant in type 2 diabetes and immunological disorders. In type 2 diabetes DPP4 inhibitors modulate the incretin hormones improving glycemic control. Proteins like GLP-1 are affected by DPP4 activity connecting it to diabetes management. In autoimmune diseases altered DPP4 expression can impact immune cell functions influencing conditions such as rheumatoid arthritis. Through its effects on ADA and associated pathways DPP4 can influence both metabolic and immune-related disorders.
